1st serious reaction to iPS-derived retinal cell transplant reported

1st serious reaction to iPS-derived retinal cell transplant reported

Masayo Takahashi, a researcher at the Japanese government-backed Riken institute, speaks at a press conference in Kobe on Jan. 16, 2018. A patient who received a transplant of retinal cells derived from so-called iPS cells from another person has suffered a swollen retina, said her project team that is implementing the world's first clinical trials of the procedure. (Kyodo) ==Kyodo

  • Product Code
  • ILEA000123485
  • Registered date
  • 2018/1/16 17:55:55
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2018 Kyodo News
  • Media size
  • 721 × 1052 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 106.52(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    1st serious reaction to iPS-derived retinal cell transplant reported

    1st serious reaction to iPS-derived retinal cell transplant reported

    The Japanese government-backed Riken institute holds a press conference in Kobe on Jan. 16, 2018, after a patient who received a transplant of retinal cells derived from so-called iPS cells from another person suffered a swollen retina. (Kyodo) ==Kyodo
      Transplants of eye cells grown from another's iPS stem cells to begin

      Transplants of eye cells grown from another's iPS stem cells to begin

      Masayo Takahashi of the Riken Center for Developmental Biology speaks at a press conference in Kobe on Feb. 6, 2017. A Japanese research team, led by Takahashi, said it will begin the world's first clinical trials involving transplanting retinal cells grown from iPS stem cells obtained from another person. (Kyodo) ==Kyodo
        Woman makes progress 1 year after world's 1st iPS cell transplant

        Woman makes progress 1 year after world's 1st iPS cell transplant

        Masayo Takahashi (R), a Riken researcher, holds a press conference in Kobe, western Japan, on Oct. 2, 2015, to announce that a woman in her 70s is making good progress in her eye disease treatment after the world's first transplant using iPS-derived cells a year ago. (Kyodo) ==Kyodo
          Riken to ask Obokata to return 600,000 yen paper submission fee

          Riken to ask Obokata to return 600,000 yen paper submission fee

          Mutsuhiro Arinobu (L), executive director of the Riken research institute, speaks at a press conference in Tokyo on March 20, 2015. Riken said it will demand that disgraced stem-cell researcher Haruko Obokata return about 600,000 yen in research paper submission fees. (Kyodo) ==Kyodo